Crucially, when they restarted the drug, they were unable to return to their previous lowest weight
Low exploratory: 1 nmol/kg subcutaneous (produces a measurable LH pulse within 30 minutes) Moderate support: 3 to 5 nmol/kg subcutaneous, daily or every other day, for 2 to 4 weeks Two forms exist: kisspeptin-54 (full-length, longer-acting, better studied in clinical trials) and kisspeptin-10 (C-terminal fragment, shorter-acting)
In this article, well explore the potential of GLP-1 patches, how they might fit into the broader treatment landscape, and what patients considering metabolic health support should know about the future of these therapies
dosing errors, contaminants, hospitalizations)